CardioExchange Archive

October 31st, 2013

EUROMAX Meets Primary Endpoint But Editorialist Raises Questions

Larry Husten, PHD

When started during transport to the hospital during a heart attack, bivalirudin (Angiox, Medicines Company) improves clinical outcomes and reduces major bleeding, though at the cost of a small but significant risk in stent thrombosis. The results of the European Ambulance Acute Coronary Syndrome (ACS) Angiography) Trial (EUROMAX) were presented on Wednesday by Phillippe Gabriel […]

---

September 16th, 2013

Selections from Richard Lehman’s Literature Review: September 16th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the AMPLIFY trial, D2B time and mortality among those undergoing primary PCI, and more.

---

September 13th, 2013

Should We Treat Nonculprit Lesions During PCI for STEMI?

David S Wald, MA MD FRCP, Richard A. Lange, MD, MBA and L. David Hillis, MD

CardioExchange’s Rick Lange and David Hillis interview David Wald about his group’s recently published findings from the PRAMI trial of “preventive” PCI in STEMI patients. Based on results of previous nonrandomized, observational studies, stenting non-infarct coronary stenoses during primary PCI has been discouraged. The Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial in 465 STEMI patients assessed whether […]

---

September 1st, 2013

A TASTE of Registry-Based Randomized Trials

Ole Frobert, MD, PhD and Harlan M. Krumholz, MD, SM

Ole Fröbert discusses his study group’s registry-based randomized trial of pre-PCI thrombus aspiration in STEMI patients.

---

September 1st, 2013

A Disruptive TASTE of the Future?

Larry Husten, PHD

Negative findings from a registry-based randomized trial of pre-PCI thrombus aspiration for STEMI patients

---

August 19th, 2013

Selections from Richard Lehman’s Literature Review: August 19th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include treating to risk, not to target; perceived job insecurity as a risk factor for incident CHD; ischemic preconditioning in patients undergoing CABG, and more.

---

April 16th, 2013

Selections from Richard Lehman’s Literature Review: April 16th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include fibrinolysis or primary PCI in STEMI, the effect of lower sodium intake on health, and the effect of increased potassium intake on CV risk factors and disease.

---

March 14th, 2013

Fibrinolysis Now or Primary PCI Later?

Frans Van de Werf, MD,PhD, Richard A. Lange, MD, MBA and L. David Hillis, MD

CardioExchange’s Rick Lange and David Hillis ask Frans Van de Werf, principal investigator for the STREAM study, about his study group’s findings and their implications for clinical practice. THE STUDY In the STREAM trial, investigators compared two treatment strategies in STEMI patients presenting early after symptom onset who were unable to undergo primary PCI within 1 hour: […]

---

March 10th, 2013

Fibrinolysis May Benefit Late-Arriving STEMI Patients

Larry Husten, PHD

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Although primary PCI has emerged as the best treatment for STEMI, most patients don’t receive this treatment within the […]

---

August 23rd, 2012

New DES Get COMFORTABLE with AMI

Richard A. Lange, MD, MBA and L. David Hillis, MD

The use of drug-eluting stents (DES) in patients with acute myocardial infarction (AMI) has recently generated concern. In two meta-analyses (De Luca et al and Kaleson et al) , the use of early-generation DES resulted in a lower risk of repeat revascularization compared with bare-metal stents (BMS) in patients with AMI, but the DES group had a 2-fold increased […]

---